Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases

Recruiting now · Not applicable

Conditions studied: Brain Metastases

In brief

Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases. The current standard of stereotactic radiotherapy (SRT) in one or three fractions is compared to fractionated stereotactic radiotherapy (fSRT) in five fractions.

Key facts

Study ID

NCT05346367

Run by

Haaglanden Medical Centre

People needed

130

Starts

2022-07-18

Expected to finish

2027-03-01

Last updated by the study team

2024-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• At least one brain metastasis of large cell cancer suitable for SRT
• Karnofsky Performance Status ≥ 70
• Ability to provide written informed consent
• New brain metastases during follow-up after surgery allowed (when outside of resection cavity area)
• New brain metastases during follow-up after previous SRT allowed (when outside of previous irradiation field)

You may not qualify if…

• Contra-indication for MRI scan
• Primary tumor of small cell lung cancer, germinoma or lymphoma
• Prior whole brain radiotherapy or SRT on the current target brain metastases (in field re-irradiation)
• Presence of leptomeningeal metastases
• Previous inclusion in the SAFESTEREO study

Where it is running

• Haaglanden Medisch Centrum — Leidschendam, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.